Entrada Therapeutics announced recipients of its inaugural Entrada Diversity, Representation, Equity and Advocacy MatterS Grant Program. Entrada DREAMS grant recipients – The Akari Foundation, Neurology and Neuromuscular Care Center and Parent Project Muscular Dystrophy – will each be awarded $25,000 to support initiatives that aim to better identify, understand and reach those within the Duchenne community who are currently underrepresented or underserved.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TRDA:
- Entrada Therapeutics to Present at Upcoming Investor Conferences
- Entrada Therapeutics appoints Chapman to its board of directors
- Entrada Therapeutics reports Q2 EPS (78c), consensus (69c)
- Entrada Therapeutics Reports Second Quarter 2023 Financial Results
- Entrada receives authorization in the UK for Phase I trial of ENTR-601-44
